Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3333587 | Seminars in Hematology | 2009 | 6 Pages |
Abstract
This review discusses the initial studies concerning the role of high-dose therapy (HDT) in multiple myeloma (MM) and gives the major conclusions drawn from this “historical period.” Later, current studies using new drugs for HDT (induction, conditioning regimen, consolidation, and maintenance) are described and the promising results of this strategy reported. Finally, the issue of HDT in the era of new drug regimens is discussed, as well as the necessity of designing future trials comparing HDT and new drug regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Michel Attal, Jean-Luc Harousseau,